Phone: +48 22 577 28 00


Accord Poland is part of Accord Healthcare, one of the fastest-growing generic and biosimilars pharmaceutical companies globally, with a demonstrated full commitment to providing patient access to effective healthcare worldwide.

Accord Poland was the first market for Accord Healthcare within Eastern Europe region in 2014, followed by the  Romanian and Czech entities in 2015. In 2014, the core of our business was focused on providing hospital solutions and building a comprehensive portfolio in this sector. 

Our CEE region has shown spectacular growth. In the first year of its operations in Poland, we hit one million Euro revenues, and we have managed to uphold a strong, consistent increase of at least 100% each year, ever since.

Accord Poland are the fastest-growing generic company based on IMS data, in the Polish pharmaceutical market for hospital and retail products. 2019 is an exciting time for Accord as we continue to add to our customer offering by the roll out of our new OTC products.

In 2018, Accord delivered roughly 6,000 products across Europe and in Poland we have launched more than 100 molecules (340 SKUs) in the last three years. We pride ourselves on our success of Day 1 launches, and a large part of this success is reflected in the fact that we continue to deliver accessible and affordable medicines to people that need them across our region.

Each year, we launch a significant number of molecules to ensure that we offer the most extensive portfolio on the market and that we are the Partner of Choice for our customers. One of our core strengths is the launch of new products. We are now the one of largest generic company in the Polish Hospital market, and one of the most important players in the Retail market. Our portfolio comprises not only generic pharmaceuticals, but also Added Value Products (biopharmaceuticals) and specialty pharmaceuticals. We are proud to have launched in Poland the first biosimilar – Accofil® - and since made significant inroads in our market share within the filgrastim market. Proof of that is Accord being the first company to have launched the biosimilar of pegfilgrastim – Pelgraz®, which recorded exceptional sales since its launch in December 2018.

Our aim is to mirror Accord’s mission of becoming a leading generics company in EMENA by 2021, by securing similar position in Poland. We are well on track to achieving this.

Fundamental to creating the growth of our company is the culture. Strong internal culture has enabled Accord to draw upon the talent that have made us the formidable company we are today in order to face the future. We believe in creating a culture that achieves with our behaviours of challenge, connect and commit, these behaviours underpin all our work; our people are at the very heart of what we do.